Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Helicobacter pylori: A concise review of the latest treatments against an old foe

Wafa A. Aldhaleei, MBBCh, MSc, MPH, Michael B. Wallace, MD, MPH, Dana M. Harris, MD and Yan Bi, MD, PhD
Cleveland Clinic Journal of Medicine August 2024, 91 (8) 481-487; DOI: https://doi.org/10.3949/ccjm.91a.24031
Wafa A. Aldhaleei
Assistant Professor, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Michael B. Wallace
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana M. Harris
Division of Internal Medicine, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Bi
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Treatment of H pylori infection - October 01, 2024

ABSTRACT

Helicobacter pylori is a significant public health concern given its high prevalence, growing rates of antibiotic resistance, and carcinogenic effect, all of which create management challenges for internists, gastroenterologists, and other specialty physicians. With almost half of the world’s human population harboring H pylori, carcinogenic sequelae are a concern to many practitioners. Recent guidelines recommend testing high-risk populations for H pylori using noninvasive or invasive methods. H pylori eradication regimens are tailored based on the presence of effective empiric therapy (local cure rates ≥ 90% for a given regimen) or antimicrobial susceptibility testing. When empiric therapy cure rates are not optimal, guidelines recommend antimicrobial susceptibility testing to improve eradication rates and reduce the progression of antibiotic resistance.

KEY POINTS
  • H pylori infection is a major health concern and is the most common carcinogenic infection worldwide.

  • Antimicrobial susceptibility testing is recommended when the cure rate of empiric therapy is less than 90%.

  • The choice of H pylori eradication therapy depends on antimicrobial susceptibility testing, the local antibiogram, cost, pill burden, and patient-related factors.

Helicobacter pylori is a gram-negative spiral microaerophilic bacterium that infects and colonizes the stomach mucosa.1,2 Nearly 50% of the world’s human population harbor H pylori,2 while the overall prevalence in the United States is less than 50%, with notable racial and ethnic disparities.1,3 H pylori infection has been linked with low socioeconomic status, poor hygiene, close interpersonal contact, and old age.1,2,4

About 10% to 20% of persons with H pylori infection will develop duodenal or gastric ulcer disease, and around 80% of non-cardia–type gastric cancers are caused by H pylori.2,5 In 1994, the World Health Organization and International Agency for Research on Cancer consensus group designated H pylori as a group 1 carcinogenic organism.2

Although antibiotic regimens to treat H pylori infection are available, disease related to H pylori remains a socioeconomic burden and a significant health concern. In 2018, H pylori was the primary cause of cancer in 37% (810,000 cases) of new infection-attributable cancer cases, making it the most common carcinogenic infection worldwide.5 H pylori eradication therapy reduces the risk of gastric cancer by about 34%.5,6

This review summarizes current evidence and guidelines on H pylori testing and management.

WHO SHOULD BE TESTED?

In 2017, the American College of Gastroenterology (ACG)4 strongly recommended H pylori testing for patients with active or past peptic ulcer disease (unless a cure is documented), low-grade gastric mucosa–associated lymphoid tissue lymphoma, or a history of early endoscopic resection of gastric cancer, and conditionally recommended nonendoscopic testing for patients under age 60 with uninvestigated dyspepsia who do not have alarm symptoms. Other scenarios in which H pylori testing is conditionally recommended include long-term nonsteroidal anti-inflammatory drug therapy, low-dose aspirin use, and unexplained iron deficiency anemia or idiopathic thrombocytopenic purpura.4

In 2018, 11 H pylori management experts suggested additional indications for H pylori testing, such as patients with a family history of gastric cancer, first-generation immigrants from high-prevalence areas, and patients of Latino or African American ethnic or racial groups.7

Table 1 summarizes key aspects of noninvasive and invasive H pylori testing.8,9 The noninvasive urea breath test and stool antigen test are highly specific and sensitive, and are widely available for use in clinical practice in the United States. Invasive molecular testing can be considered to detect infection and assess antibiotic susceptibility.

View this table:
  • View inline
  • View popup
TABLE 1

Noninvasive and invasive testing methods for Helicobacter pylori

WHAT IS STANDARD TREATMENT FOR H PYLORI?

The ACG guidelines4 recommend treating all patients with positive tests for active H pylori infection. The recommended standard therapy is a combination of a proton pump inhibitor with or without a bismuth-containing product and 1 or more of the following antibiotics: clarithromycin, metronidazole, amoxicillin, or tetracycline, given for 10 to 14 days.10,11 Clarithromycin-based regimens generally should not be offered where H pylori clarithromycin resistance exceeds 15%.4,10,11 Clarithromycin resistance is determined through antimicrobial susceptibility testing and local patterns of resistance, ie, the local antibiogram.

The overall eradication success rate with standard therapy is around 75%, with bismuth quadruple therapy having a higher success rate (about 90%) than other therapies.12 Hence, current guidelines recommend bismuth quadruple (proton pump inhibitor, bismuth, metronidazole, tetracycline) or nonbismuth quadruple (proton pump inhibitor, amoxicillin, metronidazole, clarithromycin) therapies for 10 to 14 days as first-line treatments.4,10

Treatment failure and antibiotic resistance

H pylori treatment failure can be due to many factors, including systems-, host-, and microbial-related factors.13 Systems-related factors include a lack of surveillance registries and supportive modalities for increasing medication adherence. Host factors include age, smoking history, medication nonadherence, host genetics, drug-or food-drug interaction, and insufficient dose and frequency of proton pump inhibitor or antibiotic therapy. Medication nonadherence is a common and modifiable host risk factor for eradication failure. Nonadherence can be caused by high pill burden, complicated regimens, intolerance, lack of understanding of the impact of treatment on health, and patient-clinician miscommunication. Microbial factors include primary or secondary resistance, H pylori load, and virulence through vacuolating cytotoxin A and cytotoxin-associated antigen A.13

A recent systematic review and meta-analysis showed that in the United States the prevalence of H pylori resistance to clarithromycin is 31%, metronidazole 42%, and levofloxacin 38%; the pooled resistance rates are higher than 30%.14 Resistance rates to amoxicillin, tetracycline, and rifabutin remain low.14 Metronidazole resistance may be overcome by using higher doses.13,14

WHEN IS ANTIMICROBIAL SUSCEPTIBILITY TESTING RECOMMENDED?

Antimicrobial susceptibility testing examines H pylori cultures against several antibiotics to determine sensitivity.15 Susceptibility testing is an underlying principle of antimicrobial stewardship programs that have been developed to guide treatment and limit antibiotic resistance. Such programs focus on:

  • Restricting empiric therapy and tailoring antibiotic choice to locally effective therapy based on the local antibiogram

  • Assessing treatment effectiveness using a test of cure

  • Evaluating treatment outcomes

  • Sharing test-of-cure data with local and regional clinicians, to be integrated into their antimicrobial stewardship programs.16

In general, antimicrobial susceptibility testing is recommended when empiric therapy cure rates fall below 90% or after a failed treatment attempt.15 Gastric biopsy culture with drug sensitivity testing is considered the gold standard for antibiotic susceptibility evaluation, with 100% specificity; however, it is difficult and time-consuming to perform, and requires a special medium for transportation and culture.15,17 Molecular-based testing such as polymerase chain reaction or next-generation sequencing is sensitive and specific and offers several other advantages: it can be done using stool samples and fresh or formalin-fixed, paraffin-embedded histological samples; can detect active infection and provide drug resistance information; has a rapid turnaround time (around 5 business days); and does not require special handling and transportation. However, only a limited number of laboratories can perform molecular-based testing, and it may not be covered by health insurance.17

HOW SHOULD H PYLORI ERADICATION THERAPY REGIMENS BE TAILORED?

If highly effective empiric therapy is available based on local resistance profiles, empiric treatment with bismuth quadruple therapy is recommended (Table 2).15 If empiric therapy fails, antimicrobial susceptibility testing is indicated, with treatment selection based on the results (Table 3).15

View this table:
  • View inline
  • View popup
TABLE 2

Recommended susceptibility-based Helicobacter pylori eradication therapy after failure of empiric therapy

View this table:
  • View inline
  • View popup
TABLE 3

Effective Helicobacter pylori regimens available in the United States

Penicillin allergy may hinder H pylori eradication therapy because most treatment regimens contain amoxicillin.4,18 Even though up to 20% of the general population is labeled as having a penicillin allergy, most can safely take amoxicillin after a thorough history or allergy testing.18 The ACG guidelines recommend allergy testing in individuals with a history of penicillin allergy or failed first-line therapy.4

PROTON PUMP INHIBITOR OR POTASSIUM-COMPETITIVE ACID BLOCKERS

The ability of H pylori to survive in an acidic environment necessitates the use of a proton pump inhibitor to maintain the intragastric pH above 6 and enhance the bioavailability of the antibiotics.19,20 Several proton pump inhibitor agents are available, but rabeprazole or esomeprazole 20 to 40 mg twice daily is preferable. Unlike omeprazole, lansoprazole, esomeprazole, and pantoprazole, which are mainly metabolized in the liver by CYP2C19, rabeprazole is mainly metabolized by a nonenzymatic pathway and to a lesser extent by CYP2C19.21 CYP2C19 metabolism is based on genetic predisposition (normal, intermediate, poor, rapid or ultra-rapid metabolizer), resulting in more or less acid suppression, depending on the patient. Information on the type of metabolism is only available with genetic testing. Because rabeprazole metabolism is not dependent on enzyme CYP2C19 metabolism, acid suppression is more consistent and not patient dependent.22 Esomeprazole exhibits potent inhibition of the proton pump.15

Potassium-competitive acid blockers (P-CAB) directly compete with potassium, which in turn directly inhibits hydrogen-potassium adenosine triphosphatase (proton pump).23 P-CAB agents have the following advantages over proton pump inhibitors:

  • Have direct action on the proton pump

  • Reversibly bind to the proton pump

  • Achieve full effect from the first dose

  • Are not affected by CYP2C19 genetic polymorphism

  • Have a potent antisecretory effect and a longer half-life.23,24

The US Food and Drug Administration recently approved the P-CAB vonoprazan for treating H pylori infection.25 Vonoprazan is reversible and fast-acting, has a prolonged half-life, and is not affected by diet or genetic polymorphism in drug-metabolizing enzymes.24,26

Studies of P-CAB–based regimens

A recent systematic review and meta-analysis of 8 studies focused on first-line H pylori eradication regimens found that vonoprazan-based regimens were superior to proton pump inhibitor–based therapy.26 Another systematic review and meta-analysis showed that vonoprazan-based regimens were superior to proton pump inhibitor–based therapy as second-line therapy.27 A systematic review and meta-analysis28 that comparing vonoprazan dual (with amoxicillin) therapy with vonoprazan triple (with amoxicillin and clarithromycin) therapy concluded that vonoprazan dual therapy is as effective as vonoprazan triple therapy. More interestingly, a recent systematic review and meta-analysis of randomized controlled trials29 showed eradication rates exceeding 90% in clarithromycin-sensitive strains using P-CAB–based regimens. Notably, the majority of evidence supporting the superiority of vonoprazan-based treatment was from studies conducted outside the United States.

As noted, clarithromycin-based regimens can be used when clarithromycin resistance does not exceed 15%, but with higher resistance rates, bismuth-based quadruple therapy regimens guided by susceptibility testing are preferred.4,10,11 In a multicenter, randomized controlled trial conducted in the United States and Europe, vonoprazan regimens were noninferior to standard therapy (proton pump inhibitor triple therapy).30 Eradication success rates among patients with clarithromycin- and amoxicillin-susceptible organisms were 78.5% for vonoprazan dual therapy and 84.7% for vonoprazan triple therapy, compared with 78.8% for standard therapy. In cases involving clarithromycin-resistant organisms, both vonoprazan regimens (69.6% for dual therapy and 65.8% for triple therapy) showed superiority over standard therapy (31.9%). Despite the superiority of vonoprazan regimens, eradication rates with these regimens remained below the desirable threshold of 70% when used against clarithromycin-resistant organisms. As long as clarithromycin resistance rates in the United States exceed 30%,14 vonoprazan-based regimens may not be optimal. Further studies are warranted to evaluate vonoprazan-based regimens in settings where clarithromycin resistance exceeds 15%.

Table 4 summarizes a proposed treatment approach for H pylori infection based on susceptibility testing and incorporating vonoprazan-based regimens.31

View this table:
  • View inline
  • View popup
TABLE 4

Proposed approach for Helicobacter pylori eradication therapy incorporating vonoprazan

CONCLUSION

H pylori infection is the most common carcinogenic infection worldwide. Eradication therapy is indicated for all individuals who test positive for active H pylori infection. Due to the rising burden of antibiotic resistance, susceptibility testing for H pylori infection is recommended when local empiric therapy cure rates are less than 90%; testing is also recommended after a failed first treatment attempt. Several H pylori eradication therapies, including vonoprazan-based regimens, are available. Clinicians should tailor the therapy according to antimicrobial susceptibility testing results, the local antibiogram, cost, pill burden, and patient-related factors.

DISCLOSURES

Dr. Wallace has disclosed consulting for Boston Scientific Corporation, Cosmo Pharmaceuticals, and Fujifilm, and ownership interest (stock, stock options in a publicly traded company) in Verily. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

Acknowledgment

The authors thank Dr. Ahmed Salih for his valuable support throughout the writing of this manuscript.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
View Abstract

REFERENCES

  1. ↵
    1. Hooi JKY,
    2. Lai WY,
    3. Ng WK, et al
    . global prevalence of Helicobacter pylori Infection: systematic review and meta-analysis. Gastroenterology 2017; 153(2):420–429. doi:10.1053/j.gastro.2017.04.022
    OpenUrlCrossRefPubMed
  2. ↵
    1. Robinson K,
    2. Atherton JC
    . The spectrum of Helicobacter-mediated diseases. Annu Rev Pathol 2021; 16:123–144. doi:10.1146/annurev-pathol-032520-024949
    OpenUrlCrossRef
  3. ↵
    1. Shah SC,
    2. Halvorson AE,
    3. Lee D, et al
    . Helicobacter pylori burden in the United States according to individual demographics and geography: a nationwide analysis of the Veterans healthcare system. Clin Gastroenterol Hepatol 2024; 22(1):42–50.e26. doi:10.1016/j.cgh.2023.05.016
    OpenUrlCrossRef
  4. ↵
    1. Chey WD,
    2. Leontiadis GI,
    3. Howden CW,
    4. Moss SF
    . ACG clinical guideline: treatment of Helicobacter pylori Infection [published correction appears in Am J Gastroenterol 2018; 113(7):1102]. Am J Gastroenterol 2017; 112(2):212–239. doi:10.1038/ajg.2016.563
    OpenUrlCrossRefPubMed
  5. ↵
    1. de Martel C,
    2. Georges D,
    3. Bray F,
    4. Ferlay J,
    5. Clifford GM
    . Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020; 8(2):e180–e190. doi:10.1016/S2214-109X(19)30488-7
    OpenUrlCrossRefPubMed
  6. ↵
    1. Herrero R,
    2. Park JY,
    3. Forman D
    . The fight against gastric cancer—the IARC Working Group report. Best Pract Res Clin Gastroenterol 2014; 28(6):1107–1114. doi:10.1016/j.bpg.2014.10.003
    OpenUrlCrossRefPubMed
  7. ↵
    1. El-Serag HB,
    2. Kao JY,
    3. Kanwal F, et al
    . Houston consensus conference on testing for Helicobacter pylori infection in the United States [published correction appears in Clin Gastroenterol Hepatol 2019; 17(4):801]. Clin Gastroenterol Hepatol 2018; 16(7):992–1002.e6. doi:10.1016/j.cgh.2018.03.013
    OpenUrlCrossRefPubMed
  8. ↵
    1. Kamboj AK,
    2. Cotter TG,
    3. Oxentenko AS
    . Helicobacter pylori: the past, present, and future in management. Mayo Clin Proc 2017; 92(4):599–604. doi:10.1016/j.mayocp.2016.11.017
    OpenUrlCrossRef
  9. ↵
    1. Bordin DS,
    2. Voynovan IN,
    3. Andreev DN,
    4. Maev IV
    . Current Helicobacter pylori diagnostics. Diagnostics (Basel) 2021; 11(8):1458. doi:10.3390/diagnostics11081458
    OpenUrlCrossRef
  10. ↵
    1. Malfertheiner P,
    2. Megraud F,
    3. O’Morain CA, et al
    . Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017; 66(1):6–30. doi:10.1136/gutjnl-2016-312288
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Fallone CA,
    2. Moss SF,
    3. Malfertheiner P
    . Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology 2019; 157(1):44–53. doi:10.1053/j.gastro.2019.04.011
    OpenUrlCrossRefPubMed
  12. ↵
    1. Argueta EA,
    2. Alsamman MA,
    3. Moss SF,
    4. D’Agata EMC
    . Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population. Gastroenterology 2021; 160(6):2181–2183.e1. doi:10.1053/j.gastro.2021.02.014
    OpenUrlCrossRefPubMed
  13. ↵
    1. Shah SC,
    2. Iyer PG,
    3. Moss SF
    . AGA clinical practice update on the management of refractory Helicobacter pylori Infection: expert review. Gastroenterology 2021; 160(5):1831–1841. doi:10.1053/j.gastro.2020.11.059
    OpenUrlCrossRefPubMed
  14. ↵
    1. Ho JJC,
    2. Navarro M,
    3. Sawyer K,
    4. Elfanagely Y,
    5. Moss SF
    . Helicobacter pylori antibiotic resistance in the United States between 2011 and 2021: a systematic review and meta-analysis. Am J Gastroenterol 2022; 117(8):1221–1230. doi:10.14309/ajg.0000000000001828
    OpenUrlCrossRefPubMed
  15. ↵
    1. Graham DY,
    2. Moss SF
    . Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: when, how, why. Am J Gastroenterol 2022; 117(4):524–528. doi:10.14309/ajg.0000000000001659
    OpenUrlCrossRef
  16. ↵
    1. Graham DY,
    2. Liou JM
    . Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin Gastroenterol Hepatol 2022; 20(5):973–983.e1. doi:10.1016/j.cgh.2021.03.026
    OpenUrlCrossRef
  17. ↵
    1. Dore MP,
    2. Graham DY
    . Modern approach to the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 2022; 55(suppl 1):S14–S21. doi:10.1111/apt.16566
    OpenUrlCrossRef
  18. ↵
    1. Saleem N,
    2. Howden CW
    . Update on the management of Helicobacter pylori infection. Curr Treat Options Gastroenterol 2020; 18(3):476–487. doi:10.1007/s11938-020-00300-3
    OpenUrlCrossRef
  19. ↵
    1. Scott D,
    2. Weeks D,
    3. Melchers K,
    4. Sachs G
    . The life and death of Helicobacter pylori. Gut 1998; (suppl 1):S56–S60. doi:10.1136/gut.43.2008.s56
    OpenUrlCrossRef
  20. ↵
    1. Graham DY,
    2. Fischbach L
    . Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59(8):1143–1153. doi:10.1136/gut.2009.192757
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Bakheit AH,
    2. Al-Kahtani HM,
    3. Albraiki S
    . Rabeprazole: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol 2021; 46:137–183. doi:10.1016/bs.podrm.2020.07.003
    OpenUrlCrossRef
  22. ↵
    1. Harris DM,
    2. Stancampiano FF,
    3. Burton MC, et al
    . Use of pharmacogenomics to guide proton pump inhibitor therapy in clinical practice. Dig Dis Sci 2021; 66(12):4120–4127. doi:10.1007/s10620-020-06814-1
    OpenUrlCrossRef
  23. ↵
    1. Leowattana W,
    2. Leowattana T
    . Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol 2022; 28(28):3608–3619. doi:10.3748/wjg.v28.i28.3608
    OpenUrl
  24. ↵
    1. Miftahussurur M,
    2. Pratama Putra B,
    3. Yamaoka Y
    . The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel) 2020; 13(10):276. doi:10.3390/ph13100276
    OpenUrlCrossRef
  25. ↵
    1. Gatta L,
    2. Scarpignato C
    . S1368 vonoprazan-based dual therapy and FDA-approved H pylori eradication regimens: a comparison of the available pooled data [abstract]. Am J Gastroenterol 2020; 115:S690–691.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Sun Y,
    2. Yue L,
    3. Hu W
    . Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor [‘p’[-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 2023; 79(2): 279–288. doi:10.1007/s00228-022-03430-y
    OpenUrlCrossRef
  27. ↵
    1. Shinozaki S,
    2. Kobayashi Y,
    3. Osawa H, et al
    . Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion 2021; 102(3):319–325. doi:10.1159/000504939
    OpenUrlFREE Full Text
  28. ↵
    1. Ouyang Y,
    2. Wang M,
    3. Xu YL,
    4. Zhu Y,
    5. Lu NH,
    6. Hu Y
    . Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022; 37(9):1666–1672. doi:10.1111/jgh.15917
    OpenUrlCrossRef
  29. ↵
    1. Chen PY,
    2. Tsai FP,
    3. Chen MJ,
    4. Yang HY,
    5. Wu MS,
    6. Liou JM
    . Vonoprazan-based versus proton pump inhibitor-based therapy in Helicobacter pylori eradication: an updated systematic review and meta-analysis of randomised trials. Gut 2024;73(5):872–874. doi:10.1136/gutjnl-2023-329826
    OpenUrlCrossRef
  30. ↵
    1. Chey WD,
    2. Mégraud F,
    3. Laine L,
    4. López LJ,
    5. Hunt BJ,
    6. Howden CW
    . Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology 2022; 163(3):608–619. doi:10.1053/j.gastro.2022.05.055
  31. ↵
    1. Fallone CA
    . The current role of vonoprazan in Helicobacter pylori treatment. Gastroenterology 2022; 163(3):572–574. doi:10.1053/j.gastro.2022.06.076
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (8)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 8
1 Aug 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Helicobacter pylori: A concise review of the latest treatments against an old foe
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Helicobacter pylori: A concise review of the latest treatments against an old foe
Wafa A. Aldhaleei, Michael B. Wallace, Dana M. Harris, Yan Bi
Cleveland Clinic Journal of Medicine Aug 2024, 91 (8) 481-487; DOI: 10.3949/ccjm.91a.24031

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Helicobacter pylori: A concise review of the latest treatments against an old foe
Wafa A. Aldhaleei, Michael B. Wallace, Dana M. Harris, Yan Bi
Cleveland Clinic Journal of Medicine Aug 2024, 91 (8) 481-487; DOI: 10.3949/ccjm.91a.24031
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • WHO SHOULD BE TESTED?
    • WHAT IS STANDARD TREATMENT FOR H PYLORI?
    • WHEN IS ANTIMICROBIAL SUSCEPTIBILITY TESTING RECOMMENDED?
    • HOW SHOULD H PYLORI ERADICATION THERAPY REGIMENS BE TAILORED?
    • PROTON PUMP INHIBITOR OR POTASSIUM-COMPETITIVE ACID BLOCKERS
    • CONCLUSION
    • DISCLOSURES
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Treatment of H pylori infection
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Gastroenterology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire